Ebrahim Salehifar
Overview
Explore the profile of Ebrahim Salehifar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
531
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ehsani Z, Salehifar E, Habibi E, Alizadeh-Navaei R, Moosazadeh M, Tabrizi N, et al.
Int J Hematol Oncol Stem Cell Res
. 2024 Jun;
18(2):165-173.
PMID: 38868804
Chemotherapy-induced peripheral neuropathy (CIPN) is a significant cancer treatment side effect that can influence both quality of life and treatment course. Melissa Officinalis (MO), due to its high content of...
2.
Saghafi F, Salehifar E, Ebrahimi P, Shiran M, Zaboli E, Sohrevardi S, et al.
J Pharm Biomed Anal
. 2023 Nov;
238:115839.
PMID: 37976989
Background And Objective: A high rate of interindividual variability in response to tamoxifen (TAM) in breast cancer patients with CYP2D6 polymorphism has been reported, which affects the patient's therapeutic outcome....
3.
Farzameh F, Azadbakht M, Kashi Z, Asgarirad H, Salehifar E, Mirzaee F, et al.
Food Sci Nutr
. 2023 Oct;
11(10):5918-5927.
PMID: 37823162
The seeds of (L.) Webb ex Prantl contain goitrogenic glucosinolates, such as gluconapin (3-butenyl glucosinolate). Because of the important role of iodine in the synthesis of thyroid hormones and the...
4.
Boskabadi S, Dashti A, Karevan S, Kargar-Soleimanabad S, Salehifar E
J Oncol Pharm Pract
. 2023 May;
:10781552231174790.
PMID: 37170573
To review the safety issues surrounding tyrosine kinase inhibitors (TKIs), specifically, hematological adverse effects, cardiovascular issues, renal adverse effects and nephrotoxicity, endocrine system adverse effects, concerns related to the reproductive...
5.
Salehifar E, Soltani M
Support Care Cancer
. 2023 Feb;
31(3):188.
PMID: 36847935
No abstract available.
6.
Darvishi-Khezri H, Khalilzadeh Arjmandi H, Aliasgharian A, Shaki F, Zahedi M, Kosaryan M, et al.
J Clin Lab Anal
. 2022 Nov;
36(12):e24752.
PMID: 36357338
Background And Aim: This study aimed to assess the antioxidant effects of amlodipine in transfusion-dependent β-thalassemia (TDT) patients. Methods: This crossover trial consisted of two sequences (AP and PA). In...
7.
Alikhani A, Mahmoodi K, Delavaryan L, Salehifar E, Rafiei A, Sadeghi Zavare M
Caspian J Intern Med
. 2022 Aug;
13(2):343-348.
PMID: 35919644
Background: The northern coastal regions of Iran are endemic for leptospirosis which may range from a subclinical illness to a progressively fatal disease. There has been growing evidence that inflammatory...
8.
Boskabadi J, Yousefi-Mazhin E, Salehifar E
Cancer Rep (Hoboken)
. 2022 Jul;
5(10):e1666.
PMID: 35830327
Background: Leiomyosarcoma (LMS) is an aggressive soft tissue sarcoma that is derived from smooth muscles. Ifosfamide is in use for advanced metastatic LMS. Case: A-44-years old woman with a chief...
9.
Ghanbarzamani A, Salehifar E, Jafarirad A, Hesamirostami M, Bagherzadehsaba A, Saeedi M, et al.
Iran J Pharm Res
. 2021 Dec;
20(3):178-186.
PMID: 34903980
As a common intervention among burn patients, skin graft has some risks such as infections and delay of wound healing. The aim of this study was to assess the efficacy...
10.
Nekoukar Z, Moghimi M, Salehifar E
Blood Res
. 2021 Nov;
56(4):229-242.
PMID: 34776414
Chronic myeloid leukemia (CML), a myeloproliferative disorder caused by the over activity of BCR-ABL1 (breakpoint cluster region-Abelson), has been successfully treated by Tyrosine kinase inhibitors (TKIs). While imatinib is known...